

DEPARTMENT OF DEFENSE
BREAST CANCER RESEARCH PROGRAM (BCRP)
BREAKTHROUGH AWARD PRE-APPLICATION NARRATIVE FORM

PI or Initiating PI Last Name: _____ Log Number: _____

Application Title: _____

1. What BCRP overarching challenge(s) will the proposed research address?

Eliminate the mortality associated with metastatic breast cancer

Prevent breast cancer (primary prevention)

Distinguish aggressive breast cancer from indolent cancers; overcome the problems of overdiagnosis and overtreatment

Revolutionize treatment regimens by replacing drugs that have life-threatening toxicities with safe, effective interventions

Identify what drives breast cancer growth and metastasis; identify why some breast cancers become life threatening metastases

Identify what makes the breast susceptible to cancer development

Determine why some, but not all, women get breast cancer

Determine why/how breast cancer cells lay dormant for years and then re-emerge (recurrence); determine how to eliminate dormant cells early

Other (provide justification below)

If "Other" is selected, please provide justification within the context of the breast cancer landscape [http://cdmrp.army.mil/bcrp/pdfs/bc_landscape13.pdf] in the text box below. (140 character limit, including spaces)

2. How will the proposed research lead to a solution for the overarching challenge(s)?
(2,000 character limit, including spaces)

3. How does the proposed research move beyond an incremental advancement?
(1,000 character limit, including spaces)

4. What funding level (direct costs) is requested for the proposed research?

Provide justification for the funding level. (140-character limit, including spaces)

5. What period of performance is requested?

6. Will the proposed research include a clinical trial?

Rationale:

Ductal carcinoma in situ (DCIS) constitutes 20% of all newly diagnosed breast cancers and 30-40% of breast cancers identified mammographically. DCIS lesions are believed to be direct precursors of invasive breast carcinoma (IC), but are confined to the breast duct by a basement membrane. Only 15% of DCIS recur, as either non-invasive, invasive or metastatic disease. Yet, all DCIS, when detected, are treated. Current treatment for DCIS is typically breast conserving surgery followed by radiation therapy. Therefore, many DCIS are over-treated. There is a need for molecular or pathologic features (prognostic indicators) that reliably identify those DCIS that will recur or progress. Identification of these prognostic indicators will require a better understanding of the mechanisms underlying the progression of DCIS to IC.

It is well-established in **IC** that the tumor stroma and microenvironment are critical determinants of cancer progression and therapeutic response. Breast cancer stroma is composed of multiple cell types, but principal among them is the fibroblast and the extracellular matrix (ECM) that it produces. We, and others, have shown that fibroblasts in IC differ from fibroblasts in normal breast in their ability to regulate epithelial cell growth and in their gene expression profiles. In cancer, fibroblasts are activated to remodel ECM and up-regulate expression of a variety of growth factors, and thereby, promote cancer growth, invasion, and metastasis. However, fibroblast activation and matrix remodeling are not limited to IC, but are also found to varying degrees surrounding DCIS. Several investigators have performed gene expression profiling of stromal and epithelial compartments in DCIS and IC and found few gene expression changes in the epithelium during the transition from in situ to invasive disease, but found significant expression changes in the stromal compartment. These data suggest that the stroma in DCIS plays a functional role in driving the progression of DCIS.

The role of biomechanical forces in cancer development and progression is an emerging area of study which has focused primarily on IC. Compared with normal breast, IC are stiffer, with a higher elastic modulus. The increased stiffness is largely a result of fibroblast activation and ECM remodeling. In turn, the increased tension in IC stroma causes cancer epithelial cells to up-regulate multiple signaling pathways, resulting in cancer growth, invasion, and metastasis. The biomechanical forces present in DCIS have not been specifically measured and the effect of these forces on the surrounding stroma has not been previously studied. In this proposal, we will use innovative in vitro models to measure the forces exerted by DCIS on surrounding stroma and determine the response of stromal fibroblasts. We will also investigate the use of a novel “biomarker” of recurrence and progression of DCIS to IBC – the topography of the remodeled ECM surrounding DCIS.

The experience of the initiating and partnering PIs is an ideal melding of capabilities to pursue the important and understudied topic of the biomechanical regulation of breast cancer development and progression. Dr. Andra Frost is an anatomic pathologist and breast cancer researcher with diagnostic expertise in breast cancer and a research background in fibroblast-epithelial interactions in breast cancer. Dr. Joel Berry is a bioengineer with experience in tissue and vascular modeling, bioreactor design and construction, and image analysis.

Approach:

We will test several components of our overall hypothesis, as stated in the Pre-application Narrative Form. Specific Aim 1 will focus on quantifying the biomechanical forces in DCIS. First, we will establish the presence of circumferential forces surrounding DCIS, using an in vitro model of DCIS tissue. Second, we will determine whether the circumferential forces activate stromal fibroblasts to begin ECM remodeling (Fig 1) and assess the impact of this fibroblast activation on the growth and invasion of DCIS cells. Specific Aim 2 will focus on the influence of the resulting reorganized ECM topography on the DCIS cells. We will also determine the feasibility of utilizing the topography of the remodeled collagen, specifically matrix fiber density, fiber alignment and orientation, and fiber spacing (“porosity”), to identify those DCIS most likely to progress to invasive, and potentially, metastatic carcinoma. These ECM parameters will be measured in DCIS tissues with and without IC using quantitative image analysis after laser scanning microscopy to highlight ECM arrangement.




Fig 1. Depiction of luminal (internal) pressure in DCIS extending to interstitial stroma. Two states are represented. In the first normal pressure state (left), there is normal luminal pressure and tension in the interstitial stroma. In the second state (right), increased luminal pressure from proliferating DCIS cells causes circumferential tension in the interstitial stroma, ECM and fibroblasts.